Tu, Hai-Yan
Li, Yang-Si
Yang, Jin-Ji
Chen, Hua-Jun
Jiang, Ben-Yuan
Zhong, Wen-Zhao
Yang, Xue-Ning
Wu, Yi-Long http://orcid.org/0000-0002-3611-0258
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Accepted: 6 March 2021
First Online: 16 April 2021
Declarations
:
: This work was supported by Boehringer Ingelheim. The LUX-Lung 6 study, in which the patient was enrolled while receiving treatment with afatinib, was funded by Boehringer Ingelheim. The authors received no direct compensation related to the development of the Manuscript. Editorial support was funded by Boehringer Ingelheim.
: H-YT, Y-SL, J-JY, H-JC, B-YJ, W-ZZ, and X-NY declare no potential conflicts of interest. Y-LW reports having received honoraria from AstraZeneca, Roche, BI, Pfizer, BMS, MSD, and Eli Lilly.
: H-YT designed the work, acquired, analyzed and interpreted the data, and drafted and/or substantively revised the manuscript. Y-SL drafted and/or substantively revised the manuscript. J-JY, H-JC, B-YJ, W-ZZ, and X-NY interpreted the data and drafted and/or substantively revised the manuscript. Y-LW designed the work, identified the case, interpreted the data, and drafted and/or substantively revised the manuscript. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development and have approved the final version.
: Not applicable.
: Written informed consent for publication was obtained from the patient’s family.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.